I am an Associate Professor in Nephrology within the Department of Medicine, with a secondary role at Yale Graduate School of Biological Sciences in translational biomedicine. I underwent foundational clinical training in India before relocating to the US, driven by a desire to forge a path as a physician-scientist. My clinical training culminated in the US, complemented by a post-doctoral fellowship at Mount Sinai, backed by ASN funding, that laid the groundwork for our explorations into Shroom3's role in both native and allograft kidney disease. 

Persisting as a ladder-track physician scientist at Mount Sinai, an AHA scientific development award paved the way, followed by the achievement of an independent RO1 on this research trajectory. This journey led me to my present role as an Associate Professor at Yale in 2021. Over the years, my core research has centered on a prevalent CKD-linked polymorphism, the SHROOM3 gene (and its associates, ROCK and FYN), and their associated signaling pathways - investigating Ampk in podocytes and fibrosis signals in tubular cells. Innovative mouse models have elucidated proteinuria and renal fibrosis mechanisms both in vitro and in vivo. 

Our published mechanistic investigations into the Shroom3-Fyn-Ampk axis have yielded translational insights with diagnostic and therapeutic implications, driving further RO1 and DOD funding, including recent clinical trials. My enthusiasm for translational work has driven my pursuit of expertise in a program that fuses patient data and bio-samples with in vitro and in vivo tools to tackle biological questions. As PI or Co-I, I have shaped multiple NIH-funded translational endeavors, pivotal in the field - encompassing non-HLA genetic variants like APOL1 and, more recently, mapping immune responses in COVID-19-affected kidney recipients. 

Concurrently engaging in clinical practice, I steer my funded research program while serving as Director of Research in Kidney Transplantation at Yale School of Medicine.